GLYC Stock Price, GlycoMimetics Inc Quote, Chart

Market Summary

USD1.72+0.10

Market Closed

6.17%

GLYC Stock Price

View Fullscreen

GLYC RSI Chart

GLYC Valuation

Market Cap

110.9M

Price/Earnings (Trailing)

-3

Price/Sales (Trailing)

11.1K

EV/EBITDA

30.93

Price/Free Cashflow

-3.17

GLYC Price/Sales (Trailing)

GLYC Profitability

EBT Margin

45954.78%

Return on Equity

-96.06%

Return on Assets

-81.43%

Free Cashflow Yield

-31.5%

GLYC Fundamentals

GLYC Revenue

Revenue (TTM)

10.0K

GLYC Earnings

Earnings (TTM)

-36.9M

Earnings Growth (Yr)

11.38%

Earnings Growth (Qtr)

1.35%

Breaking Down GLYC Revenue

Last 7 days

0.6%

Last 30 days

-41.9%

Last 90 days

-41.7%

Trailing 12 Months

26.5%

How does GLYC drawdown profile look like?

GLYC Financial Health

Current Ratio

6.41

GLYC Investor Care

Shares Dilution (1Y)

0.32%

Diluted EPS (TTM)

-0.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	10.0K
2022	0	179.3K	179.2K	92.6K
2021	2.2M	2.2M	1.3M	1.2M
2020	29.1M	9.0M	10.0M	10.2M
2015	0	35.1M	20.0M	20.1M
2014	0	6.8M	12.3M	15.0M
2013	12.4M	9.6M	6.8M	4.0M
2012	0	0	0	15.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of GlycoMimetics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 29, 2024	goldberg mark alan	acquired	13,752	3.00	4,584	-
Mar 29, 2024	junius daniel m	acquired	15,627	3.00	5,209	-
Mar 29, 2024	king rachel k.	acquired	10,002	3.00	3,334	-
Dec 29, 2023	king rachel k.	acquired	10,001	2.36	4,238	-
Dec 29, 2023	goldberg mark alan	acquired	13,751	2.36	5,827	-
Dec 29, 2023	andrews patricia s	acquired	12,250	2.36	5,191	-
Sep 30, 2023	goldberg mark alan	acquired	13,750	1.5	9,167	-
Sep 30, 2023	andrews patricia s	acquired	12,250	1.5	8,167	-
Sep 30, 2023	king rachel k.	acquired	10,000	1.5	6,667	-
Sep 22, 2023	rock edwin	bought	41,956	1.38	30,403	chief medical officer

Which funds bought or sold GLYC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	unchanged	-	308	1,443	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	added	25.13	101,000	271,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	sold off	-100	-58,368	-	-%
Apr 24, 2024	Hartford Financial Management Inc.	unchanged	-	2,240	10,500	-%
Apr 11, 2024	MJP ASSOCIATES INC /ADV	sold off	-100	-238,360	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	2,082,810	5,715,610	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	131	3,147,620	4,339,360	-%
Feb 26, 2024	Virtu Financial LLC	new	-	81,000	81,000	0.01%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	added	114	333,000	474,000	0.04%

Are Funds Buying or Selling GLYC?

Are funds buying GLYC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GLYC

No. of Funds

Unveiling GlycoMimetics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 29, 2024	new enterprise associates 10 l p	6.2%	4,007,977	SC 13D/A
Feb 12, 2024	new enterprise associates 10 l p	7.3%	4,721,876	SC 13D/A
Feb 09, 2024	artal international s.c.a.	13.3%	8,589,064	SC 13G/A
Jan 29, 2024	biotechnology value fund l p	7.7%	4,980,812	SC 13G/A
Feb 13, 2023	artal international s.c.a.	12.5%	6,573,798	SC 13G
Feb 10, 2023	new enterprise associates 10 l p	9.5%	4,967,530	SC 13D/A
Jul 12, 2021	blackrock inc.	1.7%	886,148	SC 13G/A
Feb 16, 2021	camber capital management lp	4.60%	2,013	SC 13G/A
Feb 12, 2021	ecor1 capital, llc	0%	0	SC 13G/A
Feb 11, 2021	biotechnology value fund l p	10.4%	4,980,812	SC 13G/A

Recent SEC filings of GlycoMimetics Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	8-K	Current Report
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
May 01, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading

Peers (Alternatives to GlycoMimetics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

GlycoMimetics Inc News

Latest updates

GlycoMimetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2015Q4	2015Q3	2015Q2	2014Q4	2014Q3	2014Q2	2014Q2	2013Q4	2013Q3
Revenue	-	-	-	-	75.00	18.00	87.00	141*	1,055	163	1,000	-	9,000	35.00	-	20,035	-	-	15,027	7,552	77.00	53.00
Operating Expenses	-9.6%	9,601	10,623	8,767	13,428	17,443	17,424	14,405	15,335	15,731	14,727	14,106	17,108	-	-	-	-	-	-	-	-	-
S&GA Expenses	-8.9%	4,312	4,732	3,845	5,455	4,548	4,142	4,237	4,188	4,011	4,058	4,235	4,440	-	-	-	-	-	-	-	-	-
R&D Expenses	-10.2%	5,288	5,891	4,923	7,973	12,895	13,282	10,167	11,147	11,720	10,670	9,871	12,668	-	-	-	-	-	-	-	-	-
EBITDA Margin	815.9%	474.88*	51.85*	26.89*	26.98*	4.19*	3.73*	2.19*	2.19*	0.48*	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80.00	-76.76	77.00	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,168	10,389	-	-6,694	8,068	-	-	-3,700
EBT Margin	826.2%	459.55*	49.61*	25.65*	25.63*	3.96*	3.52*	2.07*	2.07*	0.45*	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	11.4%	-9,078	-10,244	-8,523	-13,267	-17,421	-17,332	-14,399	-14,274	-15,562	-13,722	-14,079	-7,662	-	-	-	-	-	-	-	-	-
Net Income Margin	-632.0%	-3.69	-504.06*	-300.62*	-349.50*	-54.69*	-47.18*	-26.12*	-25.98*	-5.02*	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	3.5%	-7,635	-7,911	-8,619	-16,271	-12,809	-16,950	-13,616	-14,128	-9,724	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-14.8%	45.00	53.00	62.00	69.00	52.00	56.00	65.00	81.00	94.00	108	124	138	143	150	158	162	168	180	192	204	215
Current Assets	-15.8%	44.00	52.00	60.00	68.00	51.00	54.00	61.00	77.00	91.00	104	120	134	138	146	153	157	163	175	186	198	212
Cash Equivalents	-15.4%	42.00	49.00	58.00	65.00	48.00	52.00	60.00	77.00	90.00	102	119	132	137	143	150	155	158	171	184	196	210
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	3.7%	7.00	7.00	7.00	7.00	9.00	8.00	9.00	13.00	13.00	11.00	12.00	13.00	15.00	12.00	13.00	14.00	14.00	13.00	14.00	12.00	9.00
Current Liabilities	7.0%	7.00	6.00	7.00	7.00	9.00	8.00	9.00	13.00	12.00	10.00	10.00	11.00	12.00	10.00	10.00	11.00	11.00	10.00	11.00	8.00	9.00
Shareholder's Equity	-17.5%	38.00	47.00	55.00	62.00	43.00	48.00	56.00	68.00	82.00	97.00	112	125	128	138	146	148	154	167	179	193	205
Retained Earnings	-2.0%	-456	-447	-438	-429	-419	-409	-400	-387	-372	-355	-338	-323	-309	-293	-280	-266	-258	-243	-230	-214	-200
Additional Paid-In Capital	0.2%	495	494	493	492	462	457	456	456	454	452	450	449	438	432	426	415	413	411	409	407	406
Shares Outstanding	0.0%	64.00	64.00	64.00	64.00	54.00	52.00	52.00	52.00	51.00	51.00	51.00	51.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	109	-	-	-	31.00	-	-	-	118	-	-	-	138	-	-	-	400	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	12.1%	-7,635	-8,683	-6,974	-11,606	-7,911	-8,617	-16,230	-13,698	-12,806	-16,946	-13,611	-14,125	-9,686	-11,503	-14,551	-3,500	-12,792	-13,448	-11,394	-14,347	-9,980
Share Based Compensation	2.3%	908	888	858	870	899	914	964	1,081	1,320	1,591	1,562	1,614	1,628	1,690	1,762	1,822	1,726	1,587	1,519	1,382	1,150
Cashflow From Investing	89.8%	-801*	-7.87	-10.53	-2.20	-1*	-2.48	-41.19	-40.52	-2.45	-4.33	-5.10	-3.06	-38.17	-15.81	-6.38	-8.14	-12.36	-18.27	-74.77	-39.54	-57.00
Cashflow From Financing	-98.4%	999*	62.00	20.00	28,741	-	-	-	-	1,140	21.00	-	9,564	3,889	4,545	9,580	130	120	187	76.00	31.00	126

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GLYC Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statements of Operations and Comprehensive Loss
Revenue from collaboration and license agreements	$ 10,000	$ 75,000	$ 1,159,767
Costs and expenses:
Research and development expense	20,071,656	28,390,879	47,491,567
General and administrative expense	19,213,637	19,087,443	17,115,405
Total costs and expenses	39,285,293	47,478,322	64,606,972
Loss from operations	(39,275,293)	(47,403,322)	(63,447,205)
Interest income	2,375,873	714,520	19,768
Net loss and comprehensive loss	$ (36,899,420)	$ (46,688,802)	$ (63,427,437)
Basic net loss per common share (in dollars per share)	$ (0.58)	$ (0.89)	$ (1.23)
Diluted net loss per common share (in dollars per share)	$ (0.58)	$ (0.89)	$ (1.23)
Basic weighted-average number of common shares outstanding (in shares)	63,342,465	52,531,173	51,453,204
Diluted weighted-average number of common shares outstanding (in shares)	63,342,465	52,531,173	51,453,204

GLYC Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 41,792,830	$ 47,870,619
Prepaid expenses and other current assets	1,997,904	2,844,086
Total current assets	43,790,734	50,714,705
Prepaid research and development expenses	603,737	50,000
Operating lease right-of-use asset	767,828	751,174
Other assets	154,176	294,710
Total assets	45,316,475	51,810,589
Current liabilities:
Accounts payable	868,115	970,191
Accrued expenses	5,225,557	6,992,006
Lease liabilities	741,558	918,555
Total current liabilities	6,835,230	8,880,752
Lease liabilities, net of current portion	66,844
Total liabilities	6,902,074	8,880,752
Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock; $0.001 par value; 100,000,000 shares authorized; 64,393,744 shares issued and outstanding at December 31, 2023; 54,377,798 shares issued and outstanding at December 31, 2022	64,394	54,378
Additional paid-in capital	494,835,219	462,461,251
Accumulated deficit	(456,485,212)	(419,585,792)
Total stockholders' equity	38,414,401	42,929,837
Total liabilities and stockholders' equity	$ 45,316,475	$ 51,810,589

About GlycoMimetics Inc

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

CEO	Mr. Harout Semerjian
WEBSITE	glycomimetics.com
INDUSTRY	Biotechnology
EMPLOYEES	38

GlycoMimetics Inc Frequently Asked Questions

What is the ticker symbol for GlycoMimetics Inc? What does GLYC stand for in stocks?

GLYC is the stock ticker symbol of GlycoMimetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GlycoMimetics Inc (GLYC)?

As of Thu May 02 2024, market cap of GlycoMimetics Inc is 110.85 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GLYC stock?

You can check GLYC's fair value in chart for subscribers.

What is the fair value of GLYC stock?

You can check GLYC's fair value in chart for subscribers. The fair value of GlycoMimetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GlycoMimetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GLYC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GlycoMimetics Inc a good stock to buy?

The fair value guage provides a quick view whether GLYC is over valued or under valued. Whether GlycoMimetics Inc is cheap or expensive depends on the assumptions which impact GlycoMimetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLYC.

What is GlycoMimetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, GLYC's PE ratio (Price to Earnings) is -3 and Price to Sales (PS) ratio is 11.09 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLYC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on GlycoMimetics Inc's stock?

In the past 10 years, GlycoMimetics Inc has provided -0.175 (multiply by 100 for percentage) rate of return.